BCC surveyed life-science companies and research institutions to obtain data for this study. Included were research tools firms, diagnostics firms, drug firms, microarray and LOAC companies, and leading microarray research institutions. We also spoke with users of in vitro personalized medicine devices. In addition, we compiled data from secondary sources, including industry, trade, and government.
The author, John Bergin, has written previous BCC biotechnology reports entitled Epigenomics: Emerging Opportunities in Biomarkers, Diagnostics and Therapeutics; Global Biochip Markets: Microarrays and Lab-on-a-chip; RNA Interference in the Post-Genomics Era: Markets and Technologies; DNA Sequencing: Emerging Technologies and Markets; Biologic Imaging Reagents: Future Technologies and Markets and Synthetic Biology. Mr. Bergin has held business development, sales and marketing positions with a Fortune 500 advanced materials company, as well as executive management positions with an emerging nanotechnology company. Mr. Bergin holds the following degrees: B.S. Chemistry, M.S. Biotechnology, and Masters of Business Administration.
The total market for biochips was $2.4 billion in 2008 which increased to $2.6 billion in 2009. This is expected to grow at compound annual growth rate (CAGR) of 17.7% to reach $5.9 billion by 2014
The DNA microarrays market was nearly $1.2 billion in 2008; this further increased to $1.3 billion in 2009, this projected to reach $2.7 billion in 2014, for a 5-year CAGR of 15.2%.
Sales in the LOAC market amounted to $755 million in 2008 which increased to $817 million in 2009. This
|SOURCE S OF COMPETITIVE ADVANTAGE IN DNA MICROARRAYS 265|
Copyright©2010 PR Newswire.
All rights reserved